---

Highlights of May 2023

 

1.      Sun Pharma to acquire Taro Pharma's 100% stake in all-cash for around US$300 million through a reverse triangular merger.

2.      Zydus Promoters Eye US$200 million from Sale of Private Clinical Research Business.

3.      Temasek set to invest US$130 million in Niva Bupa for a minority stake.

4.      Lupin to acquire French firm Medisol for around INR160 crore (~US$20 million).

5.      Sirona Hygiene buys sexual wellness company Bleu.

6.      TechInvention Lifecare in partnership with Eubiologics launch oral cholera vaccine, Euvichol-Plus in India.

7.      India, S. Korea agree to step up cooperation in bio-health.

8.      Sun Pharma, Philogen join hands to commercialize skin cancer drug in Europe, Australia, New Zealand.

9.      Juno Pharmaceuticals picks up Omega Labs to expand its injectables business in Canada.

10.  Alligator Bioscience has announced that Orion Corporation has selected bispecific lead antibodies and is exercising its option to develop these molecules under the existing research collaboration and license agreement between the two companies.

11.  HiloProbe enters partnership with Biocartis.

12.  Neuro3 therapeutics acquires exclusive worldwide rights from Lundbeck.

 

Highlights at Aagami:

1.      New Client Win: Pennsylvania Pharma developing smart drug for Myelodysplastic Syndromes (MDS)

2.      New Client Win: Portland based Biotech focused on first-in-class NCEs for the treatment of arrhythmia and heart failure.

3.      New Assignment from San Francisco Client with unique technology for making low-cost Natural Melanin. Multi-sector applications including Biopharma and Consumer Health.

4.      Aagami is attending BIO International Convention 2023 (June 5-8) with 45+ meetings scheduled. This later turned out to be the best BIO Convention ever for Aagami.

INFOCUS: Select opportunities available:

For Partnering/Licensing/ Co-development:

1. Licensing/Co-development: Easy to apply world’s First Transdermal Tizanidine Patch for the Management of Spasticity. Impressive Phase 1 results. Ready to initiate Phase 2.
2. Licensing for US available: Lidocaine 10% Topical Patch; NDA approval expected in Q4 of 2023. Made using Proprietary drug formulation technology, ILTS® (Ionic Liquid Transdermal Technology). Indication: the treatment of PHN (postherpetic neuralgia).
3.  Licensing /Asset Sale -  Oral small molecule oral small molecule modulator of mutant RyR2 for the treatment of CPVT-1/ Heart Arrhythmia.
4.  Seeking Partnering/JV – Phase 2 Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia.
5. Seeking licensing/co-development partnerships: A single (monovalent) vaccine for Targeting Salmonella, ETEC / E. coli, Campylobacter, Shigella. Fulfills an unmet need for treating Bacterial Dysentery. 

For Acquisition:

1.      Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.

Seeking Investment:

1. Seeking US$5 million: A single (monovalent) vaccine for Targeting Salmonella, ETEC / E. coli, Campylobacter, Shigella. Fulfills an unmet need for treating Bacterial Dysentery.
2. $40 Million Series C: On the market, US FDA approved novel portable MRI Guided Treatment, Diagnosis and Screening, for Urology applications. California based client.
3. Seeking US$200K: Precision fermentation-based technology to produce Natural Soluble Melanin at a cost hundreds of times lower. The current round proceeds will be used to achieve milestone of making a market ready Sunscreen cream using Melanin, under Consumer Health & Wellness category.
4. Seeking US$5 million: Midwest US based Pharma First-in-Class Non-Opioid Analgesic for Pain Relief. Just $4 Million further needed to complete next milestone.